Aug 24, 2017 daratumumab plus pomalidomide and dexamethasone pomdex was evaluated in patients with relapsedrefractory multiple myeloma with. Daratumumab plus pomalidomide and dexamethasone in. Carfilzomib can partially overcome resistance in bortezomibrefractory patients and has significant efficacy in bortezomibnaive patients. Kyprolis carfilzomib is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of. Accumulated treatment cost of new therapies in multiple myeloma. Kyprolis carfilzomib dosing, indications, interactions. Carfilzomib is in a class of medications called proteasome inhibitors. Kyprolis with lenalidomide for multiple myeloma details. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth in models of multiple myeloma, hematologic, and solid tumors. If you have an allergy to carfilzomib or any other part of carfilzomib.
Community harmonized assessment of myeloma patients via an integrated oncology network1 champion1 was a phase 12, multicenter a collaboration of community oncology networks, singlearm, doseescalation study investigating carfilzomib administered on a onceweekly schedule in combination with dexamethasone to patients with relapsed, or relapsed. M carfilzomib for the indicated times followed by inhibitor wash out. Patients received carfilzomib by intravenous infusion over 2 to 10 minutes at a dose of 20 mgm2. Carfilzomib is a crystalline substance with a molecular weight of 719. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib a consensus paper by the european myeloma. Do not mix with or administer as an infusion with other medicinal products. Kyprolis is approved for use in combination with dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat multiple myeloma. As discussed in this emedtv resource, carfilzomib is used to treat a type of cancer called multiple myeloma. The nccn compendium is a derivative work of the nccn guidelines. Carfilzomib was initially fdaapproved in 2012 as monotherapy in myeloma patients who received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. Kyprolis carfilzomib for relapsed or refractory multiple. Carfilzomib marketed under the trade name kyprolis, developed by onyx pharmaceuticals is an anticancer drug acting as a selective proteasome inhibitor. The printed package leaflet of the medicinal product must state the name and address of the. Kyprolis carfilzomib is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma.
Fda approves new kyprolis carfilzomib combination therapy for. Daratumumab plus pomalidomide and dexamethasone pomdex was evaluated in patients with relapsedrefractory multiple myeloma with. Prior to each dose in cycle 1, give 250 ml to 500 ml of intravenous normal saline or other appropriate. Carfilzomib for relapsed or refractory multiple myeloma authors. Carfilzomib is an irreversible proteasome inhibitor and antineoplastic agent that is used in treatment of refractory multiple myeloma.
Empliciti elotuzumab, when used with pd or rd, is a prescription treatment for certain adults with relapsed or refractory multiple myeloma. Kyprolis carfilzomib for relapsed multiple myeloma treatment. Carfilzomib is the generic name for the trade name drug kyprolis. Kyprolis is a sterile, white to offwhite lyophilized powder and is available as a singledose 60 mg vial. Velcade can cause damage to the nerves, a condition called peripheral neuropathy. Refer to the dexamethasone prescribing information for other information on that product. After reconstitution, 1 ml of solution contains 2 mg of carfilzomib. Dec 17, 2014 carfilzomib for the treatment of patients with advanced neuroendocrine cancers the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. This medicinal product is subject to additional monitoring. Evidencebased recommendations on carfilzomib kyprolis for treating multiple myeloma in adults. Carfilzomib is associated with a low rate of serum enzyme elevations during treatment and has been implicated to rare instances of clinically apparent, acute liver injury some of which have been fatal. Patients received carfilzomib by intravenous infusion over 2 to 10 minutes at a dose of 20. Kyprolis carfilzomib is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. Please see indication and important safety information.
Kyprolis, inncarfilzomib european medicines agency. Infuse over 10 or 30minutes depending on the kyprolis dose regimen see dosage and administration 2. Highlightsof prescribing information these highlights do not include all the information needed to use kyprolis safely and effectively. Oct 28, 2019 carfilzomib is practically insoluble in water and very slightly soluble in acidic conditions. Kyprolis carfilzomib is an antineoplastic agent indicated to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with velcade bortezomib and an immunomodulatory therapy. Sep 28, 2012 carfilzomib is a secondgeneration proteasome inhibitor with welldocumented clinical activity as a single agent in patients with relapsedrefractory multiple myeloma. What do i need to tell my doctor before i take carfilzomib. Do not use kyprolis if you are allergic to carfilzomib or any of the other ingredients of this medicine listed in section 6. In some cases, health care professionals may use the trade name kyprolis when referring to the generic drug name carfilzomib. Carfilzomib is administered as a 210minute infusion on days 1, 2, 8, 9, 15, and 16 of a 28day cycle at a starting dose of 20 mgm 2 for cycle 1 and a target dose of 27 mgm 2 thereafter. Listing a study does not mean it has been evaluated by the u. Phase 3 arrow study of onceweekly kyprolis carfilzomib. Kyprolis is approved for use in combination with dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat.
Three cases of druginduced thrombotic microangiopathy tma. Thrombocytopenia has been reported with ninlaro with platelet nadirs typically occurring between days 1421 of each 28day cycle and recovery to baseline by the start of the next cycle. Carfilzomib, a selective proteasome inhibitor approved in the usa in 2012, is a single agent for relapsed and refractory multiple myeloma. Twice weekly 2056 mgm2 regimen by 30minute infusion. Promacta eltrombopag tablets, for oral use promacta eltrombopag for oral suspension initial u.
Synchronous trophozoites were treated with 100 nm or 1. When combined with dexamethasone, kyprolis is administered intravenously as a 30 minute infusion on two consecutive days, each week for three weeks days 1, 2, 8, 9, 15, and 16 followed by a 12day rest period days 17 to 28 as shown in table 2. If patient starting dose was 10 mg daily, resume at 5 mg less than previous dose. Revlimid lenalidomide is a prescription medicine, used to treat adults with multiple myeloma mm in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation a type of stem cell transplant that uses your own stem cells. First described in 1848, mm is characterized by a proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraprotein m protein. Highlights of prescribing information initiate promacta at. Kyprolis is a sterile, white to offwhite lyophilized powder and is available as a singledose 10 mg, 30 mg or 60 mg vial. Highlights of prescribing information these highlights do not include all the information needed to use promacta safely and effectively. Kyprolis carfilzomib for injection, for intravenous use initial u. This article explains how this chemotherapy regimen works to kill cancer cells. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.
Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. Nplate is a prescription medicine used to treat low blood platelet counts thrombocytopenia in adults with immune thrombocytopenia itp when certain medicines or surgery to remove your spleen have not worked well enough. It uses a similar set of steps to inserting as an image, but does something different as a result. Moreau p, hullin c, garban f, yakoubagha i, benboubker l, attal m, et al. The fda has designated carfilzomib as an orphan drug for for the treatment of multiple myeloma.
Carfilzomib is classified as a proteasome inhibitor. Carfilzomib for the treatment of patients with advanced neuroendocrine cancers the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Immune thrombocytopenia itp treatment nplate romiplostim. Kyprolis carfilzomib dose, indications, adverse effects. Carfilzomib injection is used alone and in combination with dexamethasone or lenalidomide revlimid and dexamethasone to treat people with multiple myeloma a type of cancer of the bone marrow who have already been treated with other medications.
Infusion time is 10 minutes and remains consistent throughout the regimen. Kyprolis is a sterile, white to offwhite lyophilized powder and is. Administration kyprolis can be administered in a 50ml or 100ml intravenous bag of 5% dextrose injection, usp. The mtd of the regimen was dose level 1 carfilzomib 2027 mgm2, pomalidomide 4 mg, dexamethasone 40 mg. You may feel muscle weakness, tingling, burning, pain, and loss of feeling in your hands and feet, any of which can be severe. Carfilzomib for the treatment of patients with advanced. Treatments received, total dosage, responses, toxicities. Kyprolis carfilzomib for injection, for intravenous use. Ninlaro ixazomib capsules, for oral use hepatotoxicity. Carfilzomib can partially overcome resistance in bortezomibrefractory patients and has significant efficacy in. Dose carfilzomib at a maximum body surface area bsa of 2. Carfilzomib pharmacokinetics absorption bioavailability. Kyprolis is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Kyprolis summary of product characteristics smpc emc. Carfilzomib, pomalidomide, and dexamethasone for relapsed or. Randomized, openlabel, phase 3 study in subjects with relapsed and refractory multiple myeloma receiving carfilzomib in combination with dexamethasone, comparing onceweekly versus twiceweekly carfilzomib dosing trial evaluated approximately 478 patients with relapsed and refractory multiple myeloma who have received at least. Hydrate patients to reduce the risk of renal toxicity and of tumor lysis syndrome tls.
Multiple myeloma mm is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance mgus to plasma cell leukemia. Dec 04, 2019 a study showed that these patients taking carfilzomib with certain other drugs melphalan and prednisone had more very bad and sometimes deadly side effects compared to a certain other drug. Sep, 2019 carfilzomib kyprolis news and resources for multiple myeloma patients, caregivers, and others interested in carfilzomib and multiple myeloma. Carfilzomib is practically insoluble in water and very slightly soluble in acidic conditions. Highlightsof prescribing information kyprolis safely and. Nov 20, 2019 you must read the package leaflet of all medicines that you take in combination with kyprolis so that you understand the information related to those medicines. Fulltext pdf pcn225 two costeffectiveness analyses of the use of carfilzomib in combination with lenalidomide plus. Side effects of kyprolis carfilzomib, warnings, uses. Auc is doseproportional over the dose range of 2036 mgm 2. Insert a pdf file as an object into a powerpoint presentation to insert a pdf file as an object into a powerpoint presentation, you make it available to those youre sharing the presentation with. Community harmonized assessment of myeloma patients via an integrated oncology network1 champion1 was a phase 12, multicenter a collaboration of community oncology networks, singlearm, doseescalation study investigating carfilzomib administered on a onceweekly schedule in combination with dexamethasone to patients with relapsed, or relapsed and refractory mm. Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the nterminal threoninecontaining active sites of the 20s proteasome, the proteolytic core particle within the 26s proteasome.
Highlights of prescribing information these highlights. A singlearm trial enrolled 266 patients with multiple myeloma refractory to the most recent therapy who had received prior treatment with bortezomib and an immunomodulatory agent imid. Medication use recorded from informed consent through 30 days following the last dose of any study drug. Carfilzomib kyprolis may be considered medically necessary for the fdaapproved indication of treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. May 08, 2014 carfilzomib, a selective proteasome inhibitor approved in the usa in 2012, is a single agent for relapsed and refractory multiple myeloma. Administration infuse over 10 or 30 minutes depending on the kyprolis dose regimen see dosage and administration 2. It also explains why this drug is only approved for adults.
Incidence and management of adverse events in patients with. Parasites were placed in fresh media, and proteasome activities of all samples were determined by mv151 labeling at 10 hr after inhibitor washout. Independent, uptodate news and information for the multiple myeloma community. Carfilzomibdexamethasone versus bortezomibdexamethasone in. Store in accordance with information listed on the product insert. Carfilzomib for relapsed or refractory multiple myeloma the lancet. You must read the package leaflet of all medicines that you take in combination with kyprolis so that you understand the information related to those medicines.
443 83 600 291 76 1074 807 1072 971 1515 1395 1269 196 859 766 186 152 784 829 1222 309 725 1207 469 885 1174 727 684 1228 30